Express Scripts ESRX unveils its next round of earnings this Tuesday, October 25, 2011. Here is Benzinga's everything-that-matters guide for this Tuesday's third quarter earnings announcement.
Earnings and Revenue:
Here's how the company's reported EPS has stacked up against analyst estimates in the past:
Quarter | Q2 | Q1 | Q4 | Q3 |
EPS Estimate | $0.71 | $0.70 | $0.70 | $0.65 |
EPS Actual | $0.71 | $0.66 | $0.71 | $0.65 |
Stock Performance:
- Long-term shareholders are already wary of 12-month losses prior to the announcement
Average Stock Rating:
Competitors:
- American Dental Partners ADPI: Moderate Buy with a $0.28 recent quarter EPS
- AMERIGROUP AGP: Hold with a $0.83 recent quarter EPS
- Centene CNC: Hold with a $0.64 recent quarter EPS
- Magellan Health Services MGLN: Moderate Buy with a $1.07 recent quarter EPS
The medical services company's industry has seen price/earnings growth of 1.1% during the current fiscal year.
Finally, a description of the company's main areas of operation: Express Scripts is a pharmacy benefit management (PBM) company, providing services like retail network pharmacy management and patient care contact centers to its clients in North America.
Take Action:
That's your advanced look at Express Scripts' upcoming earnings numbers -- be ready to take quick action if the company's report contains any surprises. Also, check back in with us after the announcement for a full recap and what-to-do-next guide.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.